HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset

Core Insights - HOOKIPA Pharma Inc. is presenting preclinical data for its HB-700 program targeting KRAS mutated cancers at the 6th Annual RAS-Targeted Drug Development Summit in Boston from September 24-26, 2024 [1][2] Company Overview - HOOKIPA is a clinical-stage biopharmaceutical company focused on developing next-generation immunotherapeutics using its proprietary arenavirus platform [3] - The company aims to induce specific, robust, and durable CD8+ T cells and antibodies to combat cancers and serious infectious diseases [3] - HOOKIPA's pipeline includes therapies for HPV16+ cancers, KRAS mutated cancers, and partnerships with Gilead for hepatitis B and HIV-1 treatments [3] Product Development - The HB-700 program is designed to target the most prevalent KRAS mutations found in pancreatic, colorectal, and lung cancers [2] - The preclinical dataset for HB-700 has shown safety, induction of target-specific CD8+ T-cells, and effective target cell killing in various animal and translational models [2] - The program has received IND clearance from the FDA in Q2 2024, making it ready for Phase 1 trials [2]